REGNRegeneron PharmaceuticalsInvite-only sign-up
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Melanoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 48 (planned)
- Started
- Apr 14, 2025
- Main results expected
- Oct 10, 2029
- Fully finished
- Oct 10, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613
Measured over: Up to 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06848088 · record last updated 2026-07-13 · checked 2026-11-09 15:47 UTC